These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23171841)

  • 1. [Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease].
    Andrieux K; Couvreur P
    Biol Aujourdhui; 2012; 206(3):185-90. PubMed ID: 23171841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
    Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
    Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease.
    Andrieux K; Couvreur P
    Ann Pharm Fr; 2013 Jul; 71(4):225-33. PubMed ID: 23835020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
    Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bionanotechnologies for treatment and diagnosis of Alzheimer's disease.
    Moghimi SM
    Nanomedicine; 2011 Oct; 7(5):515-8. PubMed ID: 21616169
    [No Abstract]   [Full Text] [Related]  

  • 6. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor.
    Prades R; Guerrero S; Araya E; Molina C; Salas E; Zurita E; Selva J; Egea G; López-Iglesias C; Teixidó M; Kogan MJ; Giralt E
    Biomaterials; 2012 Oct; 33(29):7194-205. PubMed ID: 22795856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
    Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
    J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
    Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
    J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer's Disease.
    Pinheiro RGR; Granja A; Loureiro JA; Pereira MC; Pinheiro M; Neves AR; Reis S
    Pharm Res; 2020 Jul; 37(7):139. PubMed ID: 32661727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gold nanoparticles as amyloid-like fibrillogenesis inhibitors.
    Hsieh S; Chang CW; Chou HH
    Colloids Surf B Biointerfaces; 2013 Dec; 112():525-9. PubMed ID: 24060166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotherapeutic strategies for the treatment of Alzheimer's disease.
    Gu X; Chen H; Gao X
    Ther Deliv; 2015 Feb; 6(2):177-95. PubMed ID: 25690086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of peptides in blood-brain barrier nanotechnology.
    Teixidó M; Giralt E
    J Pept Sci; 2008 Feb; 14(2):163-73. PubMed ID: 18085720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug delivery to the brain with nanoparticles].
    Aliautdin RN; Kreuter J; Kharkevich DA
    Eksp Klin Farmakol; 2003; 66(2):65-8. PubMed ID: 12962052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.